- Trials with a EudraCT protocol (442)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
442 result(s) found for: Cognitive tests.
Displaying page 1 of 23.
EudraCT Number: 2015-001850-13 | Sponsor Protocol Number: GLP-1/MCI | Start Date*: 2015-09-11 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA | |||||||||||||
Full Title: Long-acting exenatide: a tool to stop cognitive decline in patients with mild cognitive impairment with or without dysglycemia? | |||||||||||||
Medical condition: Moderate cognitive impairment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001975-12 | Sponsor Protocol Number: V00191 PO 202 | Start Date*: 2007-07-18 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT - IDPF | |||||||||||||
Full Title: Evaluation of the effect of 6 months treatment with V0191 on symptoms changes in patients with Mild Cognitive Impairment. Multicentre, randomised, double-blind, placebo-controlled study in parallel... | |||||||||||||
Medical condition: Mild Cognitive Impairment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) FI (Completed) ES (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000473-83 | Sponsor Protocol Number: PET-tau-FACEHBI | Start Date*: 2021-12-15 |
Sponsor Name:Fundació ACE-Institut Català de Neurociències Aplicades | ||
Full Title: PET imaging study of the brain tau deposit in individuals with subjective cognitive decline and mild cognitive impairment: FACEHBI cohort. | ||
Medical condition: Subjective cognitive impairment and mild cognitive decline in evaluation for diagnosis of Alzheimer's Disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-006195-39 | Sponsor Protocol Number: EarlyAD-PET | Start Date*: 2012-02-29 | |||||||||||||||||||||
Sponsor Name:Skånes universitetssjukhus | |||||||||||||||||||||||
Full Title: An open-label study to compare the prognostic value of (18F)Flutemetamol PET-imaging with longitudinal biomarker data in healthy volunteers and patients with mild cognitive impairment | |||||||||||||||||||||||
Medical condition: Dementia and cognitive impairment; in particular mild cognitive impairment and Alzheimer's disease | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: SE (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003111-58 | Sponsor Protocol Number: AD-4833/TOMM40_301 | Start Date*: 2013-09-20 | |||||||||||
Sponsor Name:Takeda Development Centre Europe Ltd | |||||||||||||
Full Title: A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer’s... | |||||||||||||
Medical condition: Mild cognitive impairment due to Alzheimer’s disease | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Prematurely Ended) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003188-13 | Sponsor Protocol Number: CONIVAD | Start Date*: 2016-09-23 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI | |||||||||||||
Full Title: Pilot study on the association choline alphoscerate-nimodipine in patients with subcortical vascular cognitive impairment | |||||||||||||
Medical condition: Subcortical vascular cognitive impairment | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001751-17 | Sponsor Protocol Number: IIBSP-DON-2022-43 | Start Date*: 2023-07-27 |
Sponsor Name:Institut de Recerca Hospital de la Santa Creu i Sant Pau - IIB Sant Pau | ||
Full Title: Multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of donepezil versus placebo in mild cognitive impairment associated with Parkinson's disease | ||
Medical condition: Parkinson's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-000986-40 | Sponsor Protocol Number: EVT 101/1002 | Start Date*: 2007-08-07 |
Sponsor Name:Evotec NeurosciencesGmbH | ||
Full Title: A double blind, placebo controlled study to investigate the role of NMDA receptor NR2B subunit selective antagonism on cognitive functions and neurophysiology in healthy subjects as measured with MRI | ||
Medical condition: Investigation of cognitive function and neurophysiology. | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-002899-34 | Sponsor Protocol Number: V 5 Protocol | Start Date*: 2007-09-18 |
Sponsor Name:Newcastle Upon tyne Hospitals NHS Foundation Trust | ||
Full Title: Pilot Controlled Clinical Trial of Salvia Officinalis (Sage) for cognitive impairments in Parkinson's Disease | ||
Medical condition: Cognitive impairment in Parkinson's Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-024119-15 | Sponsor Protocol Number: rs4680-tolcapona | Start Date*: 2014-04-10 | |||||||||||
Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra | |||||||||||||
Full Title: EVALUATION OF THE EFFICACY OF TOLCAPONE AS A GENOTYPE-BASED TARGETED COGNITIVE ENHANCER IN SCHIZOPHRENIA, BASED ON THE POLYMORPHISM RS4680 | |||||||||||||
Medical condition: Esquizofrenia crónica controlada. (10 pacientes con el genotipo val/val y 10 pacientes con el genotipo met/met) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Restarted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004187-30 | Sponsor Protocol Number: CO17730 | Start Date*: 2011-12-14 | |||||||||||
Sponsor Name:Avraham Pharmaceuticals Ltd. | |||||||||||||
Full Title: A 36-month, multi-centre, randomized double-blind placebo-controlled study to evaluate the safety and efficacy of low dose Ladostigil in patients with Mild Cognitive Impairment (MCI) | |||||||||||||
Medical condition: Patient with Mild Cognitive Impairment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004297-34 | Sponsor Protocol Number: 236252 | Start Date*: 2018-03-31 | |||||||||||
Sponsor Name:Aston University | |||||||||||||
Full Title: A placebo controlled double blind randomised controlled proof of concept study of zolpidem for the treatment of motor and cognitive deficits in late-stage Parkinson’s | |||||||||||||
Medical condition: Parkinson's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000342-19 | Sponsor Protocol Number: IIT-2017/02 | Start Date*: 2018-10-18 |
Sponsor Name:Otto-von-Guericke-Universität Magdeburg, Medizinische Fakultät | ||
Full Title: Prospective, randomized, double-blind clinical trial phase II for the anti-inflammatory effects of Curazink (zinc histidine) for 8 weeks in elderly patients with mild cognitive impairment in Alzhei... | ||
Medical condition: Included are patients with the presence of a moderate or pronounced zinc deficienc and the diagnosis of a mild cognitive disorder, which may be due to an additional investigation (amyloid PET and /... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003567-66 | Sponsor Protocol Number: T817MAEU201 | Start Date*: 2019-06-11 | ||||||||||||||||
Sponsor Name:FUJIFILM Toyama Chemical Co., Ltd. | ||||||||||||||||||
Full Title: A Phase 2 multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T 817MA in patients with mild cognitive impairment due to Alzheimer... | ||||||||||||||||||
Medical condition: Mild cognitive impairment due to Alzheimer's Disease or mild Alzheimer's Disease. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) ES (Ongoing) HU (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004109-27 | Sponsor Protocol Number: 2.12.05 | Start Date*: 2006-03-24 |
Sponsor Name:Neuropsychiatric clinic | ||
Full Title: A double-blind, placebo-controlled multi-centre trial of memantine in patients with Parkinsons’ disease dementia or dementia with Lewy bodies | ||
Medical condition: Parkinsons disease (PD)and dementia with Lewy bodies (DLB) are both common disease of the elderly. The majority of patients who survive for more than 10 years with PD eventually develope dementia ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-001846-42 | Sponsor Protocol Number: CAQW051A2104 | Start Date*: 2007-10-05 | ||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
Full Title: A 4-week, parallel-group, randomized, double-blind, placebo-controlled, adaptive proof of concept study of AQW051 at up to three dose levels for the treatment of patients with findings consistent w... | ||||||||||||||||||
Medical condition: Mild Alzheimer’s disease (AD) and amnestic mild cognitive impairment (amnestic MCI) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-003891-11 | Sponsor Protocol Number: LMT-01-02-18 | Start Date*: 2019-07-16 | |||||||||||
Sponsor Name:Life Molecular Imaging SA | |||||||||||||
Full Title: An Open Label, Single Center Study, to evaluate the Safety and Imaging Characteristics of [18F]PI-2620 as PET Radioligand for Imaging Tau deposition in the brains of subjects with amnestic mild cog... | |||||||||||||
Medical condition: Alzheimer's Disease Amnestic Mild Cognitive Impairment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003705-17 | Sponsor Protocol Number: LUMC-NECH-201801-ACA | Start Date*: 2019-03-22 |
Sponsor Name:LUMC | ||
Full Title: Prevention of neuropsychiatric adverse effects caused by dexamethasone: translational insights from a placebo-controlled trial with hydrocortisone. | ||
Medical condition: Neuropsychiatric adverse effects which can be caused by dexamethasone. For example delirium, anxiety, depression, mania and psychosis. But also cognitive impairment and sleep disturbance. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2016-000679-25 | Sponsor Protocol Number: IIBSP-CAN-2016-16 | Start Date*: 2016-05-31 |
Sponsor Name:INSTITUT DE RECERCA HSCSP | ||
Full Title: A prospective, randomized, double-blind and placebo-controlled, parallel group, phase II study to compare the efficacy and safety of candesartan versus placebo on cognitive impairment associated wi... | ||
Medical condition: Parkinson's Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-003209-92 | Sponsor Protocol Number: EVP-6124-016 | Start Date*: 2013-10-22 | ||||||||||||||||
Sponsor Name:Forum Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel, 26 Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cogniti... | ||||||||||||||||||
Medical condition: Cognitive impairment associated with schizophrenia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) IT (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
